Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4

4(100.0%)

4Total

Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04667507Phase 4Completed

Pharmacokinetics of Aqueous Dexamethasone

Role: lead

NCT06650358Enrolling By Invitation

Clinical Outcomes of Patients with LAL+ in At Least One Eye

Role: lead

NCT01296191Phase 4Completed

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

Role: lead

NCT01253239Completed

Evaluation the TECNIS IOL in Both Eyes VS the ReZoom IOL in One and TECNIS IOL in the Opposite

Role: lead

NCT01001806Phase 4Completed

A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification

Role: lead

NCT01021761Phase 4Completed

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

Role: lead

All 6 trials loaded